New hope for rare scleroderma: experimental drug MTX-474 enters phase 2 trial

NCT ID NCT07287670

First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests whether the experimental drug MTX-474 can safely reduce skin thickening in people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin to harden and can damage internal organs. About 85 adults with early-stage disease will receive either MTX-474 or a placebo for 24 weeks. The main goal is to measure changes in skin thickness using a standard scoring system.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • EncompaSSc site in Baltimore, MD

    RECRUITING

    Baltimore, Maryland, 21224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • EncompaSSc site in Boston, MA

    RECRUITING

    Boston, Massachusetts, 02118, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • EncompaSSc site in Clearwater, FL 33765

    RECRUITING

    Clearwater, Florida, 33765, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • EncompaSSc site in Newport Beach, CA 92663

    RECRUITING

    Newport Beach, California, 92663, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • EncompaSSc site in Tampa, FL

    RECRUITING

    Tampa, Florida, 33606, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.